Skip to main content
Top
Published in: International Urology and Nephrology 8/2018

01-08-2018 | Nephrology - Original Paper

Are iso-osmolar, as compared to low-osmolar, contrast media cost-effective in patients undergoing cardiac catheterization? An economic analysis

Authors: Swapnil Hiremath, Ayub Akbari, George A. Wells, Benjamin J. W. Chow

Published in: International Urology and Nephrology | Issue 8/2018

Login to get access

Abstract

Purpose

Contrast-induced acute kidney injury is a prominent complication following cardiac catheterization, though the risk has progressively decreased in recent times with appropriate risk stratification and use of safer contrast agents. Despite data supporting further lowering of risk with the iso-osmolar agent, iodixanol, uptake has lagged, perhaps due to increased upfront cost of this agent. We undertook an economic analysis to estimate the cost-effectiveness of a strategy utilizing iodixanol compared to using a low-osmolar contrast agent.

Methods

We created a Markov model to evaluate the two strategies, and included a differential relative risk of contrast-induced acute kidney injury, based on a systematic review of the literature. Downstream clinical events, including need for dialysis and mortality, were modeled using data from existing published literature. A third-party payer perspective was utilized for the analysis and presentation of the primary economic analysis.

Results

The strategy of using iodixanol dominated in both the low-risk and high-risk base case analyses. However, the difference was quite small in the low-risk scenario (lifetime cost: C$678,034 vs. C$678,059 and life expectancy: 19.80 vs. 19.72 years). The difference was more marked (life expectancy 15.65 vs. 14.15 years and cost C$680,989 vs. C$682,023) in the high-risk case analysis. This was robust across most of the variables tested in sensitivity analyses.

Conclusion

The use of iodixanol, compared with low-osmolar contrast agents, for cardiac catheterization, results in a small benefit clinical outcomes, and in a savings in direct healthcare costs. Overall, our analysis supports the use of iodixanol for cardiac catheterization, especially in patients at high risk of acute kidney injury.
Literature
7.
go back to reference Aspelin P, Aubry P, Fransson S-G, Strasser R, Willenbrock R, Berg KJ et al (2003) Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348(6):491–499CrossRefPubMed Aspelin P, Aubry P, Fransson S-G, Strasser R, Willenbrock R, Berg KJ et al (2003) Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348(6):491–499CrossRefPubMed
8.
go back to reference Sharma SK (2008) Iodinated contrast media and contrast-induced nephropathy: is there a preferred cost-effective agent? J Invasive Cardiol 20(5):245–248PubMed Sharma SK (2008) Iodinated contrast media and contrast-induced nephropathy: is there a preferred cost-effective agent? J Invasive Cardiol 20(5):245–248PubMed
10.
15.
go back to reference Wyman RM, Safian RD, Portway V, Skillman JJ, McKay RG, Baim DS (1988) Current complications of diagnostic and therapeutic cardiac catheterization. J Am Coll Cardiol 12(6):1400–1406CrossRefPubMed Wyman RM, Safian RD, Portway V, Skillman JJ, McKay RG, Baim DS (1988) Current complications of diagnostic and therapeutic cardiac catheterization. J Am Coll Cardiol 12(6):1400–1406CrossRefPubMed
18.
go back to reference Johannesson M, QALYs (1994) HYEs and individual preferences—a graphical illustration. Soc Sci Med 39(12):1623–1632CrossRefPubMed Johannesson M, QALYs (1994) HYEs and individual preferences—a graphical illustration. Soc Sci Med 39(12):1623–1632CrossRefPubMed
Metadata
Title
Are iso-osmolar, as compared to low-osmolar, contrast media cost-effective in patients undergoing cardiac catheterization? An economic analysis
Authors
Swapnil Hiremath
Ayub Akbari
George A. Wells
Benjamin J. W. Chow
Publication date
01-08-2018
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 8/2018
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-018-1874-1

Other articles of this Issue 8/2018

International Urology and Nephrology 8/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.